probucol has been researched along with Coronary Restenosis in 26 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thus, treatment with probucol, a potent antioxidant agent that has been shown to reduce restenosis after balloon angioplasty, may be an effective strategy to prevent intimal hyperplasia after stenting." | 9.12 | Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: a randomized study. ( Abizaid, AC; Belló-Klein, A; Brito, FS; Caixeta, A; Clausell, N; da Silva, LF; Mazzotti, NG; Nunes, GL; Theodoro, MP, 2006) |
| "Carvedilol is an antioxidant that inhibits smooth muscle cell proliferation and migration, whereas probucol is a vascular protectant and reduces stent restenosis by improving the lumen dimension at the stent placement site." | 5.33 | Effect of anti-oxidant (carvedilol and probucol) loaded stents in a porcine coronary restenosis model. ( Ahn, YK; Cha, KS; Cho, JG; Hong, YJ; Hur, SH; Hyun, DW; Jeong, MH; Kang, JC; Kim, JH; Kim, KB; Kim, MH; Kim, W; Park, HW; Park, JC; Park, JT, 2005) |
| " Thus, treatment with probucol, a potent antioxidant agent that has been shown to reduce restenosis after balloon angioplasty, may be an effective strategy to prevent intimal hyperplasia after stenting." | 5.12 | Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: a randomized study. ( Abizaid, AC; Belló-Klein, A; Brito, FS; Caixeta, A; Clausell, N; da Silva, LF; Mazzotti, NG; Nunes, GL; Theodoro, MP, 2006) |
| " The powerful antioxidant probucol has been shown to prevent coronary restenosis after balloon angioplasty in the Multivitamins and Probucol (MVP) trial and other clinical studies." | 4.81 | Prevention of restenosis with antioxidants: mechanisms and implications. ( Grégoire, J; L'Allier, PL; Tardif, JC, 2002) |
| " A striking exception is probucol, which retards atherosclerosis in carotid arteries and restenosis of coronary arteries after angioplasty." | 3.73 | Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. ( Adams, MR; Beck, K; Choy, K; Croft, KD; Kathir, K; Lau, AK; Li, C; Mori, TA; Stocker, R; Tanous, D; Witting, PK; Wu, BJ, 2006) |
| "02 for the dose-response relationship; P< or =0." | 2.71 | Effects of AGI-1067 and probucol after percutaneous coronary interventions. ( Bourassa, MG; Glass, M; Grégoire, J; Guertin, MC; L'Allier, PL; Lambert, J; Laramée, L; Lespérance, J; Reeves, F; Schwartz, L; Tardif, JC; Title, L, 2003) |
| "When probucol was administered in a dose of 250 mg/day for 7-10 days before transluminal balloon coronary angioplasty and then for 6 months after surgery, the incidence of restenosis decreased to 25% compared to 45% in the control (without probucol therapy)." | 2.71 | Low daily dose of antioxidant probucol decreases incidence and severity of restenosis after transluminal coronary balloon angioplasty. ( Belenkov, YN; Kaminnyi, AI; Konovalova, GG; Kukharchuk, VV; Lankin, VZ; Perepelitsa, EI; Polevaya, TY; Provatorov, SI; Samko, AN; Sozykin, AL; Tikhaze, AK, 2005) |
| " AGI-1067 is the metabolically stable monosuccinic acid ester of probucol, and a potent phenolic antioxidant representing a novel class of orally bioavailable compounds termed vascular protectants." | 2.44 | AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis. ( Eisert, C; Malinin, A; Ong, S; Serebruany, VL, 2007) |
| "Probucol has reduced post-percutaneous coronary intervention (PCI) restenosis and progression of carotid atherosclerosis in clinical trials." | 2.43 | Antioxidants and atherosclerosis: emerging drug therapies. ( Tardif, JC, 2005) |
| "Probucol has reduced postpercutaneous coronary intervention (PCI)-restenosis and progression of carotid atherosclerosis in clinical trials." | 2.43 | Antioxidants: the good, the bad and the ugly. ( Tardif, JC, 2006) |
| "Carvedilol is an antioxidant that inhibits smooth muscle cell proliferation and migration, whereas probucol is a vascular protectant and reduces stent restenosis by improving the lumen dimension at the stent placement site." | 1.33 | Effect of anti-oxidant (carvedilol and probucol) loaded stents in a porcine coronary restenosis model. ( Ahn, YK; Cha, KS; Cho, JG; Hong, YJ; Hur, SH; Hyun, DW; Jeong, MH; Kang, JC; Kim, JH; Kim, KB; Kim, MH; Kim, W; Park, HW; Park, JC; Park, JT, 2005) |
| "Probucol was then tested in vivo in 8 coronary arteries of 4 pigs (1000 mg/day orally beginning 7 days before stenting) and was compared to placebo (10 coronary arteries, 5 pigs) 28 days after stenting." | 1.32 | Effect of probucol on neointimal thickening in a stent porcine restenosis model. ( Daida, H; Kurata, T; Miyauchi, K; Sato, H; Yokoyama, T, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 21 (80.77) | 29.6817 |
| 2010's | 4 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, M | 1 |
| Xu, B | 1 |
| Kandzari, DE | 1 |
| Wu, Y | 1 |
| Yan, H | 1 |
| Chen, J | 1 |
| Qian, J | 1 |
| Qiao, S | 1 |
| Yang, Y | 1 |
| Gao, RL | 1 |
| Guerra, E | 1 |
| Byrne, RA | 3 |
| Kastrati, A | 3 |
| Harada, Y | 1 |
| Colleran, R | 1 |
| Kufner, S | 1 |
| Giacoppo, D | 1 |
| Rheude, T | 1 |
| Michel, J | 1 |
| Cassese, S | 1 |
| Ibrahim, T | 1 |
| Laugwitz, KL | 1 |
| Mehilli, J | 1 |
| Iijima, R | 1 |
| Schulz, S | 1 |
| Pache, J | 1 |
| Seyfarth, M | 1 |
| Schömig, A | 1 |
| Chen, SL | 1 |
| Ye, F | 1 |
| Zhang, JJ | 1 |
| Zou, JJ | 1 |
| Qian, XS | 1 |
| Li, F | 1 |
| Yang, S | 1 |
| Ge, Z | 1 |
| Shan, SJ | 1 |
| Li, XB | 1 |
| Xu, T | 1 |
| Kan, J | 1 |
| Lin, L | 1 |
| Han, YL | 1 |
| Belenkov, IuN | 1 |
| Batyraliev, TA | 1 |
| Pershukov, IV | 1 |
| Samko, AN | 2 |
| Tardif, JC | 5 |
| Grégoire, J | 3 |
| Schwartz, L | 1 |
| Title, L | 1 |
| Laramée, L | 1 |
| Reeves, F | 1 |
| Lespérance, J | 1 |
| Bourassa, MG | 1 |
| L'Allier, PL | 3 |
| Glass, M | 1 |
| Lambert, J | 1 |
| Guertin, MC | 1 |
| Okamoto, S | 1 |
| Ishisu, R | 1 |
| Yamakado, T | 1 |
| Kitai, T | 1 |
| Ishiwata, S | 1 |
| Yamaguchi, T | 1 |
| Wakeyama, T | 1 |
| Ogawa, H | 1 |
| Iida, H | 1 |
| Takaki, A | 1 |
| Iwami, T | 1 |
| Mochizuki, M | 1 |
| Tanaka, T | 1 |
| Doggrell, SA | 1 |
| Lavoie, MA | 1 |
| Yokoyama, T | 1 |
| Miyauchi, K | 1 |
| Kurata, T | 1 |
| Sato, H | 1 |
| Daida, H | 1 |
| Kim, W | 1 |
| Jeong, MH | 1 |
| Cha, KS | 1 |
| Hyun, DW | 1 |
| Hur, SH | 1 |
| Kim, KB | 1 |
| Hong, YJ | 1 |
| Park, HW | 1 |
| Kim, JH | 1 |
| Ahn, YK | 1 |
| Kim, MH | 1 |
| Cho, JG | 1 |
| Park, JT | 1 |
| Park, JC | 1 |
| Kang, JC | 1 |
| Kaminnyi, AI | 1 |
| Lankin, VZ | 1 |
| Sozykin, AL | 1 |
| Provatorov, SI | 1 |
| Konovalova, GG | 1 |
| Perepelitsa, EI | 1 |
| Tikhaze, AK | 1 |
| Polevaya, TY | 1 |
| Kukharchuk, VV | 1 |
| Belenkov, YN | 1 |
| Franks, AM | 1 |
| Gardner, SF | 1 |
| Wu, BJ | 1 |
| Kathir, K | 1 |
| Witting, PK | 1 |
| Beck, K | 1 |
| Choy, K | 1 |
| Li, C | 1 |
| Croft, KD | 1 |
| Mori, TA | 1 |
| Tanous, D | 1 |
| Adams, MR | 1 |
| Lau, AK | 1 |
| Stocker, R | 1 |
| Xu, G | 1 |
| Li, XS | 1 |
| Huang, WQ | 1 |
| Huang, H | 1 |
| Nunes, GL | 1 |
| Abizaid, AC | 1 |
| Theodoro, MP | 1 |
| Brito, FS | 1 |
| Caixeta, A | 1 |
| da Silva, LF | 1 |
| Mazzotti, NG | 1 |
| Belló-Klein, A | 1 |
| Clausell, N | 1 |
| Serebruany, VL | 1 |
| Malinin, A | 1 |
| Eisert, C | 1 |
| Ong, S | 1 |
| Yang, YB | 1 |
| Yang, YX | 1 |
| Su, B | 1 |
| Tang, YL | 1 |
| Zhu, BY | 1 |
| Hu, ZW | 1 |
| Li, GY | 1 |
| Li, YJ | 1 |
| Liao, DF | 1 |
| Douglas, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Randomized Trial of Rapamycin- and Zotarolimus-eluting Stents for the Reduction of Coronary Restenosis[NCT00598533] | Phase 4 | 3,002 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Randomized Comparison of 3 Limus Agent-Eluting Stents for the Reduction of Coronary Restenosis[NCT00332397] | Phase 4 | 1,007 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for probucol and Coronary Restenosis
| Article | Year |
|---|---|
Pharmacological inhibition of coronary restenosis: systemic and local approaches.
Topics: Anti-Bacterial Agents; Antioxidants; Cilostazol; Coronary Restenosis; Drug Delivery Systems; Drug-El | 2014 |
[Invasive cardiology: focus on restenosis. Part II].
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antioxidants; Cardiac Surgical Procedures; Corona | 2002 |
[Prevention of restenosis after PTCA and patient's QOL].
Topics: Angioplasty, Balloon, Coronary; Antihypertensive Agents; Atherectomy, Coronary; Coronary Restenosis; | 2003 |
[Prevention of postangioplasty restenosis].
Topics: Angioplasty, Balloon, Coronary; Atherectomy, Coronary; Clinical Trials as Topic; Coated Materials, B | 2003 |
Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Clinical Trials as Topic; Coronar | 2003 |
Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Clinical Trials as Topic; Coronary | 2003 |
Prevention of restenosis with antioxidants: mechanisms and implications.
Topics: Angioplasty, Balloon, Coronary; Antioxidants; Clinical Trials as Topic; Coronary Artery Disease; Cor | 2002 |
Antioxidants and atherosclerosis: emerging drug therapies.
Topics: Antioxidants; Arteriosclerosis; Clinical Trials as Topic; Coronary Restenosis; Humans; Oxidative Str | 2005 |
AGI-1067: a novel vascular protectant for prevention of restenosis.
Topics: Animals; Antioxidants; Clinical Trials as Topic; Coronary Restenosis; Drugs, Investigational; Humans | 2006 |
Antioxidants: the good, the bad and the ugly.
Topics: Angioplasty, Balloon, Coronary; Antioxidants; Atherosclerosis; Coronary Restenosis; Humans; Oxidativ | 2006 |
AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Topics: Animals; Antioxidants; Atherosclerosis; Blood Platelets; Coronary Artery Disease; Coronary Restenosi | 2007 |
Pharmacologic approaches to restenosis prevention.
Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coated Materials, Biocompatible; Coronary Artery Disease | 2007 |
8 trials available for probucol and Coronary Restenosis
| Article | Year |
|---|---|
First report of a novel polymer-free dual-drug eluting stent in de novo coronary artery disease: results of the first in human BICARE trial.
Topics: Cardiovascular Agents; China; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Drug Com | 2014 |
Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Coronary Angiography; Coronary Restenosis; Cor | 2016 |
A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.
Topics: Aged; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Disease-Free Survival; Drug-Elut | 2009 |
Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
Topics: Absorbable Implants; Aged; Cardiovascular Agents; Chi-Square Distribution; China; Coronary Angiograp | 2013 |
Effects of AGI-1067 and probucol after percutaneous coronary interventions.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Coronary D | 2003 |
Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Benzimidazoles; Biphenyl Co | 2003 |
Low daily dose of antioxidant probucol decreases incidence and severity of restenosis after transluminal coronary balloon angioplasty.
Topics: Angioplasty, Balloon, Coronary; Antioxidants; Coronary Restenosis; Coronary Stenosis; Humans; Male; | 2005 |
Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: a randomized study.
Topics: Aged; Antioxidants; Blood Vessel Prosthesis Implantation; Coronary Restenosis; Female; Humans; Hyper | 2006 |
6 other studies available for probucol and Coronary Restenosis
| Article | Year |
|---|---|
Effect of probucol on neointimal thickening in a stent porcine restenosis model.
Topics: Animals; Antioxidants; Coronary Restenosis; Coronary Vessels; Disease Models, Animal; Probucol; Rand | 2004 |
Heart disease. Keeping arteries open after angioplasty.
Topics: Angioplasty, Balloon, Coronary; Antioxidants; Coronary Restenosis; Humans; Probucol; Radiotherapy; S | 1997 |
Effect of anti-oxidant (carvedilol and probucol) loaded stents in a porcine coronary restenosis model.
Topics: Animals; Antioxidants; Carbazoles; Carvedilol; Coronary Restenosis; Disease Models, Animal; Probucol | 2005 |
Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Coronary Restenosis; Diabetes Mellitus, Type 2; Free Ra | 2006 |
[Effect of probucol and losartan on growth factors after balloon angioplasty in rabbits].
Topics: Angioplasty, Balloon; Animals; Anticholesteremic Agents; Coronary Restenosis; Drug Therapy, Combinat | 2006 |
Probucol mediates vascular remodeling after percutaneous transluminal angioplasty via down-regulation of the ERK1/2 signaling pathway.
Topics: Angioplasty, Balloon; Animals; Antioxidants; Atherosclerosis; Caveolin 1; Cell Movement; Cell Prolif | 2007 |